Buying these already crosses something off your to-do list. So go ahead and snooze, you deserve a nap.

The Ashes to Glasses cocktail is a beautiful creation mixing Del Maguey Vida mezcal with Don Julio reposado, lemon juice, ...

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

First, let's take a look at Lilly's path to GLP-1 dominance and consider why the stock has taken off recently. Novo Nordisk entered this market first, back in 2017, with Ozempic, which regulators ...

In response to a planned healthcare reform initiative in Germany, which would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the ...

AlzeCure Pharma CEO Martin Jonsson and CSO Johan Sandin. (AlzeCure Pharma) Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease ...

Eli Lilly's Jacob Van Naarden says Lilly is using the financial strength from its GLP-1 drugs like Mounjaro and Zepbound to fund its new dealmaking strategy. Van Naarden recently became Lilly's head ...

BERLIN, June 3 (Reuters) - Eli Lilly (LLY.N), opens new tab will halve its originally planned investment of €2.3 ‌billion ($2.67 billion) in Germany, CEO Dave Ricks told the Handelsblatt business ...

June 8 (Reuters) - Eli Lilly (LLY.N), opens new tab shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it ...

Positive data on Eli Lilly's obesity and diabetes candidate retatrutide highlighted the Amercian Diabetes Association Scientific Sessions last weekend in New Orleans. () It’s a sign of the times that ...

Ascidian is named after a marine invertebrate also known as the sea squirt because of the creature’s ability to re-engineer its RNA. (iStock / Getty Images Plus) “We can probably edit almost any gene, ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...